GW Pharma just won the industry's first cannabinoid nods from NICE, which endorsed Epidyolex for a rare epilepsy and Sativex for MS muscle spasticity.
Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.
ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.
ICER is calling out drugmakers for price increases that are not supported by clinical data, But some of the companies have bones to pick.
Riding high on FDA and EU approvals in triple-negative breast cancer, Roche’s Tecentriq hoped for a win from NICE. The drugmaker didn’t get it.
Just days after releasing a report suggesting that three JAK inhibitors for rheumatoid arthritis wouldn't be cost-effective, ICER is backtracking.
JAK inhibitors to treat rheumatoid arthritis, like AbbVie's Humira follow-up, Rinvoq, may not be cost effective, ICER says in a new report.
Here's a finding to incorporate into the pricing debate: New cancer meds often add little benefit for patients, but carry significantly higher prices.
Despite efforts by Novartis to secure funding for Aimovig in England, NICE rejected the migraine prevention drug.
Heart benefits offered by Novo Nordisk's oral version of its hit drug for Type 2 diabetes, Ozempic, won't justify its price, ICER said.